Form 8-K - Current report:
SEC Accession No. 0001558370-25-006598
Filing Date
2025-05-07
Accepted
2025-05-07 07:00:21
Documents
17
Period of Report
2025-05-07
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mtva-20250507x8k.htm   iXBRL 8-K 48262
2 EX-99.1 mtva-20250507xex99d1.htm EX-99.1 29036
3 GRAPHIC mtva-20250507x8k001.jpg GRAPHIC 9107
4 GRAPHIC mtva-20250507xex99d1001.jpg GRAPHIC 16884
5 GRAPHIC mtva-20250507xex99d1002.jpg GRAPHIC 60286
  Complete submission text file 0001558370-25-006598.txt   338135

Data Files

Seq Description Document Type Size
6 EX-101.SCH mtva-20250507.xsd EX-101.SCH 3410
7 EX-101.LAB mtva-20250507_lab.xml EX-101.LAB 15926
8 EX-101.PRE mtva-20250507_pre.xml EX-101.PRE 10053
19 EXTRACTED XBRL INSTANCE DOCUMENT mtva-20250507x8k_htm.xml XML 4806
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
MetaVia Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 25919204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)